CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03891784
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:38.421782+00:00
Published At: 2026-01-14T00:00:00+00:00
Record Updated At: 2026-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Digestive System Neuroendocrine Neoplasm", "Digestive System Neuroendocrine Tumor", "Foregut Neuroendocrine Tumor", "Hindgut Neuroendocrine Tumor", "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm", "Metastatic Digestive System Neuroendocrine Neoplasm", "Midgut Neuroendocrine Tumor", "Pancreatic Neuroendocrine Tumor", "Refractory Digestive System Neuroendocrine Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-14"
protocolSection.identificationModule.nctId: "NCT03891784"
protocolSection.identificationModule.officialTitle: "A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.